← Markets

Olema Pharmaceuticals, Inc.

OLMA · NASDAQ

Market closed$11.47$0.400000 (+3.61%)After hours $11.48 · +0.09%

Key statistics

Previous close$11.07
Open$10.93
Day high$11.88
Day low$10.91
52-week high$36.26
52-week low$4.40
Market cap1.00B
Volume1.46M
Average volume1.45M
P/E ratio-5.68
Forward P/E—
EPS-2.02
Dividend yield0.00%

Market context

Why it moved

OLMA shares rose on elevated volume amid broad buying interest, with the stock pushing higher on positive market momentum as buyers drove the price up from its opening levels throughout the trading session.

HotelsFacebookOrgRitzcarltonyachtcollectionInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Olema Pharmaceuticals rose sharply, buoyed by growing investor attention ahead of its critical OPERA-01 Phase 3 data readout for palazestrant (oral SERD) expected in H2 2026. Despite insider selling pressure — including the CLO's complete liquidation of ~$600K in shares in March — Wall Street remains broadly bullish with 11 Buy ratings and a consensus price target of $44.10, well above current levels. UBS upgraded its healthcare sector outlook, citing a warming M&A environment and product catalysts as tailwinds for biotech names, adding broader sector support to the move.

3.6134

July 15, 2026Olema Pharmaceuticals closed the regular session little changed but surged roughly 4.5% in after-hours trading, drawing attention back to a stock that sits far below its consensus analyst price target of $44.10 despite a Moderate Buy rating from most covering firms. The after-hours move stands in contrast to a muted healthcare sector (XLV essentially flat in extended hours), suggesting stock-specific interest may be at play. Investor backdrop remains mixed: Wall Street Zen recently upgraded OLMA from 'strong sell' to 'sell,' while UBS has flagged biotech as a beneficiary of recovering M&A activity and product catalysts, and broader market sentiment has been lifted by a cooler-than-expected CPI report.

-0.2532

July 14, 2026Olema Pharmaceuticals closed essentially flat in after-hours trading, holding steady near $11.85 amid a mixed backdrop for biotech stocks. Wall Street Zen's recent upgrade from 'strong sell' to 'sell' highlights the cautious sentiment surrounding the clinical-stage oncology company, which focuses on women's cancers and reported Q1 EPS of -$0.52 in line with estimates. Despite the muted price action, the consensus analyst view remains constructive—11 of 14 analysts hold Buy ratings with an average price target of $44.10, a stark contrast to the current share price. Healthcare sector headwinds persist broadly, with XLV under pressure ahead of major earnings reports from J&J, UnitedHealth, and Abbott this week.
July 14, 2026Olema Pharmaceuticals edged modestly lower, closing down about 0.5%, as broader market headwinds weighed on small-cap biotech names. The wider market pulled back on renewed U.S.-Iran military tensions that sent oil prices surging over 5% and rattled equity sentiment. Despite the near-term softness, the clinical-stage oncology company focused on women's cancers trades at a steep discount to its consensus analyst price target of $44.10, with 11 of 14 covering analysts rating it Buy or better — even as Wall Street Zen's upgrade from 'strong sell' to 'sell' highlights lingering skepticism among some. The broader biotech backdrop remains constructive, with Goldman Sachs and Jim Cramer both flagging the sector as a prime M&A target amid robust deal activity in oncology.

-0.5038

July 9, 2026Olema Pharmaceuticals shares fell nearly 3%, underperforming the healthcare sector as a broader market risk-off selloff — driven by President Trump declaring the U.S.-Iran ceasefire 'over,' sending oil prices surging 5%+ — weighed on small-cap biotech names. Despite the day's pressure, the broader biotech backdrop remains constructive: Jim Cramer recently called biotech 'the hottest group in the market,' citing a favorable FDA regulatory shift expected to unleash a wave of M&A, with companies like Eli Lilly and Gilead actively acquiring late-stage assets — a narrative that could benefit clinical-stage firms like Olema as potential targets.

-2.8504

July 3, 2026Olema Pharmaceuticals gained nearly 5% as momentum from its broad Russell Growth index inclusion — spanning the Russell 2000, 2500, 3000, and Microcap Growth benchmarks added in late June — continued to drive institutional visibility and trading interest. The index additions, which followed earlier inclusion in the S&P Biotech index, are drawing index-tracking and quantitative funds to the clinical-stage oncology company. Healthcare was the strongest S&P sector on the day, providing a favorable backdrop, while Olema's pipeline catalysts — including palazestrant's late-stage breast cancer trials and a May collaboration with Bayer to evaluate OP-3136 in prostate cancer — remain the key binary drivers ahead.

4.6358

July 1, 2026Olema Pharmaceuticals fell after a post-Russell index inclusion rally ran into profit-taking, with shares declining roughly 3.4% on above-average volume — more than 1.7x its typical daily turnover. The pullback follows a ~22% surge tied to the company's late-June addition across six Russell Growth benchmarks (Russell 2000, 2500, 3000, 3000E, Small Cap Comp, and Microcap Growth), which broadened its institutional visibility but did not change the binary nature of its clinical story. Investors continue to watch upcoming data from palazestrant's late-stage breast cancer trials and OP-3136 combinations, including a new Bayer collaboration, as the core catalysts for this pre-revenue oncology biotech.

-3.4373

July 1, 2026Olema Pharmaceuticals closed up ~2.5% on above-average volume — nearly double its daily average — driven by its broad inclusion across multiple Russell Growth indices, spanning the Russell 2000, 2500, 3000, 3000E, Small Cap Comp, and Microcap Growth benchmarks. The additions expand Olema's institutional visibility and could attract passive fund inflows, though analysts note the move is more about trading dynamics than fundamentals, with the real story remaining in late-stage clinical catalysts for palazestrant and OP-3136, the latter backed by a Bayer collaboration. In after-hours trading, shares are giving back some of those gains, falling ~4%.

2.541

Moomoo · July 14, 2026LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24Simply Wall Street · July 2, 2026Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?Seeking Alpha · May 15, 2026Olema: The Market Overreacted To Roche's SERD FailureStock Titan · May 12, 2026Palazestrant nears pivotal Phase 3 data in metastatic breast cancerSimply Wall Street · May 3, 2026Olema Adds Deal Veteran Prakash Raman To Guide Oncology PartnershipsInvestor's Business Daily · March 9, 2026Roche Tumbles, Taking Olema With It, On A High-Profile FailureInvesting.com · March 9, 2026Olema Pharmaceuticals stock tumbles 41% on Roche trial data
Mt Newswire · May 26, 2026Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy
Benzinga · May 26, 2026Olema Pharma Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate OP-3136 In Combination With NUBEQA In Patients With mCRPC
Benzinga · May 21, 2026Olema Pharmaceuticals Reports Initial Clinical Data From The Phase 1 Study of OP-3136, A KAT6 Inhibitor, At 2026 ASCO Annual Meeting; OP-3136 Monotherapy Was Well-tolerated With No Dose-limiting Toxicities Observed And No Discontinuations Due To Treatment-related Adverse Events; OP-3136 Shows Evidence Of Anti-tumor Activity Across Multiple Solid Tumor Types
Benzinga · May 13, 2026Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35
Benzinga · May 12, 2026Olema Pharmaceuticals Q1 EPS $(0.52) Beats $(0.53) Estimate
Mt Newswire · May 12, 2026Olema Pharmaceuticals Q1 Net Loss Widens
Mt Newswire · May 12, 2026Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q1 Net Loss $0.52 a Share, vs. FactSet Est of $0.52 Loss
Benzinga · April 21, 2026Olema Pharma To Present Phase 1 OP-3136 Data And Phase 3 OPERA-02 Trial Updates At ASCO 2026

Peers

S&P 500SPX · $7,457.69-1.01%Tango Therapeutics, Inc.TNGX · $28.56+3.33%NewAmsterdam Pharma Company N.V.NAMS · $31.68+2.03%Denali Therapeutics Inc.DNLI · $23.29+2.46%Crinetics Pharmaceuticals, Inc.CRNX · $83.86-0.06%Apogee Therapeutics, Inc.APGE · $134.00-0.06%Spyre Therapeutics, Inc.SYRE · $100.23+6.49%Larimar Therapeutics, Inc.LRMR · $3.70+0.82%Rezolute, Inc.RZLT · $4.61+5.49%Agios Pharmaceuticals, Inc.AGIO · $39.61+2.30%BriaCell Therapeutics Corp.BCTX · $3.73-3.12%ACADIA Pharmaceuticals Inc.ACAD · $25.60-0.12%